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The encapsulation of cisplatin by cucurbit[7]uril (Q[7]) and multinuclear platinum complexes linked via
a 4,4′-dipyrazolylmethane (dpzm) ligand by Q[7] and cucurbit[8]uril (Q[8]) has been studied by NMR
spectroscopy and molecular modelling. The NMR studies suggest that some cisplatin binds in the
cucurbituril cavity, while cis-[PtCl(NH3)2(H2O)]+ only binds at the portals. Alternatively, the
dpzm-linked multinuclear platinum complexes are quantitatively encapsulated within the cavities of
both Q[7] and Q[8]. Upon encapsulation, the non-exchangeable proton resonances of the multinuclear
platinum complexes show signiﬁcant upﬁeld shifts in 1H NMR spectra. The H3/H3* resonances shift
upﬁeld by 0.08 to 0.55 ppm, the H5/H5* shift by 0.9 to 1.6 ppm, while the methylene resonances shift
by 0.74 to 0.88 ppm. The size of the resonance shift is dependent on the cavity size of the encapsulating
cucurbituril, with Q[7] encapsulation producing larger shifts than Q[8]. The upﬁeld shifts of the dpzm
resonances observed upon cucurbituril encapsulation indicate that the Q[7] or Q[8] is positioned
directly over the dpzm linking ligand. The terminal platinum groups of trans-[{PtCl(NH3)2}2l-dpzm]2+
(di-Pt) and trans-[trans-{PtCl(NH3)2}2-trans-{Pt(dpzm)2(NH3)2}]4+ (tri-Pt) provide a barrier to the on
and off movement of cucurbituril, resulting in binding kinetics that are slow on the NMR timescale for
the metal complex. Although the dpzm ligand has relatively few rotamers, encapsulation by the larger
Q[8] resulted in a more compact di-Pt conformation with each platinum centre retracted further into
each Q[8] portal. Encapsulation of the hydrolysed forms of di-Pt and tri-Pt is considerably slower than
for the corresponding Cl forms, presumably due to the high-energy cost of passing the +2 platinum
centres through the cucurbituril portals. The results of this study suggest that cucurbiturils could be
suitable hosts for the pharmacological delivery of multinuclear platinum complexes.
Introduction
Cisplatin is an effective drug in the treatment of human testicular,
ovarian, lung, bladder, head and neck cancers.1 The continued
use of cisplatin, however, is limited by both natural and acquired
resistance.2 This resistance can arise from several factors which
include: drug deactivation by increased intracellular glutathione
levels, reduced cellular uptake, enhanced DNA repair and/or
increased tolerance of platinum–DNA lesions.3 In addition,
cisplatin is limited by its side-effects, which include neuro- and
nephrotoxicity, nausea and vomiting. These side-effects limit the
drug to doses between 60 and 120 mg m−2.4
Much of the synthetic research over the last 20 years has
focused on drugs that are able to overcome both resistance and
the dose-limiting side-effects.5–9 This has led to the approval of
carboplatin and oxaliplatin for clinical use,3 and the development
of multinuclear platinum complexes.10–18
Multinuclear platinum complexes are thought to overcome re-
sistance through novelDNAbindingmodes.14–19 Whereas cisplatin
and carboplatin mostly form rigid, short-range intrastrand DNA
School of Physical, Environmental and Mathematical Sciences, University
College,University ofNewSouthWales,AustralianDefenceForceAcademy,
Canberra, ACT, 2600, Australia. E-mail: g-collins@adfa.edu.au; Fax: +61
(02) 6268 8002
† Electronic supplementary information (ESI) available: Colour versions
of Fig. 8 and 9. See DOI: 10.1039/b513197a
‡ Current address: School of Science, Food and Horticulture, University
of Western Sydney, Campbelltown, NSW, 2560, Australia.
adducts, the multinuclear complexes are generally identiﬁed as
forming ﬂexible, long-range interstrand adducts.14–19 In addition,
these complexes are taken up by cells to a greater extent than
cisplatin.20–29 Particularly important features of multinuclear plat-
inumdrugs are their ability to overcome both natural and acquired
resistance and show activity in cancers that are deﬁned as p53-
mutant.30–33
One such complex, BBR3464 (Fig. 1) has entered phase II
clinical trials and three other complexes, BBR3571, BBR3610
and BBR3611 have shown strong clinical potential.3,17,34–38 While
these complexes are active at concentrations 10- to 100-fold lower
than cisplatin, they are also more toxic. From phase I trials the
maximum tolerated dose of BBR3464 was found to be between
0.9 and 1.1 mg m−2, while other BBR complexes appear to be even
more toxic.35–38 Recent trials have also shown that these complexes
may be degraded (and hence deactivated) by plasma proteins
before they reach their intracellular target; possibly explaining
the low activity of BBR3464 in phase II trials to date.35–38
Recently, our group has identiﬁed a mechanism by which
both the toxicity of these drugs could be decreased, and their
degradation reduced within the human body.39 Cucurbit[n]uril
(Q[n]) is a barrel-shaped molecule, containing a hydrophobic
cavity, formed by the acid catalysed condensation of glycoluril
and formaldehyde (Fig. 1).40–44 Cucurbit[n]urils can be synthesised
in a variety of sizes (n = 5, 6, 7, 8 and 10), and are capable of
encapsulating smaller molecules within their cavities.45–48 In the
case of cucurbit[7]uril (Q[7]) we have shown that its encapsulation
of the dinuclear platinum complex trans-[{PtCl(NH3)}2l-dpzm]2+
This journal is © The Royal Society of Chemistry 2006 Dalton Trans., 2006, 451–458 | 451
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Fig. 1 (A) Structure of cisplatin and a generic multinuclear platinum
complex with a range of linking ligands that yield: BBR3463; di-Pt and
tri-Pt and (B) cucurbit[n]uril.
(di-Pt, Fig. 1) slows the platinum complex’s rate of reaction with
guanosine, without affecting its normal DNA binding mode or its
in vitro cytotoxicity.39 In contrast, other researchers have shown
that the encapsulation of oxaliplatin with Q[7] reduced the drugs
reactivity to both guanosine and methionine, but that in vitro
cytotoxicity was also reduced.49
In this study, we extend our previous preliminary report of the
encapsulation of di-Pt by Q[7].39 We have studied encapsulation by
Q[7] and Q[8] of cisplatin, di-Pt and the related trinuclear complex
trans-[trans-{PtCl(NH3)2}2—trans-{Pt(dpzm)2(NH3)2}]4+ (tri-Pt)
(see Fig. 1). These were studied by NMR spectroscopy and
molecular modelling in an effort to achieve a more detailed
understanding of the relationship of the host to the guest in a
potential protective drug delivery vehicle role.
Experimental
Materials
Transplatin, cisplatin, pyrazole, tetrabutylammonium hydroxide
were purchased from the Aldrich Chemical Company. D2O
was purchased from Cambridge Isotope Laboratories. Q[7],
Q[8] and the metal complexes were synthesised as previously
described.20,40,50,51 Aqua forms of the metal complexes were pre-
paredby the additionof 2mol equivalents ofAgNO3 as anaqueous
solution. The resultant AgCl was removed by centrifugation
and the resulting solution freeze dried to remove water before
dissolution inD2O.All solventswere used as provided andaqueous
solutions were made usingMilli-Q water, coming from aMillipore
four-stage water puriﬁcation unit.
Encapsulation of platinum complexes
The encapsulated platinum complexes were obtained by either
direct crystallisation (1) or by titration of the metal complex into a
cucurbituril solution (2). (1) Equimolar, or in some cases a two- or
three-fold excess of cucurbituril, amounts of the platinum complex
and cucurbituril were dissolved in hot water containing 20 mM
NaCl. Slow evaporation of the solution resulted in crystals of
cucurbituril-encapsulated metal complexes. (2) Aliquots of the
platinum complex dissolved in D2O (approx. 2 mM) were directly
titrated into a 5 to 10 mL solution of the appropriate cucurbituril
(2–4 mM) in D2O to give the desired molar ratio. Aliquots of the
solution were then taken for analysis by NMR spectroscopy.
NMR
1D and 2D NMR spectra were obtained on a Varian Unityplus-
400 spectrometer operating at 400 MHz for 1H and 85 MHz for
195Pt. 1D 1H NMR spectra were recorded over a spectral width of
5000 Hz using 256 transients. 2D NOESY spectra were obtained
over a spectral width of 4200Hzwith amixing time of 300ms using
2048 points in the t2 dimension with 256 t1 increments and with a
total recycle time of 1.7 s. All 1H NMR were referenced to DSS
(0 ppm) at 25 ◦C. 195Pt NMRwere externally referenced toK2PtCl4
(−1631 ppm) and collected using a spectral width between 75 000
and 100 000 Hz, with between 1000 and 10 000 transients and a
recycle time of 0–0.4 s.
Molecular modelling
Encapsulated multinuclear complexes were modelled using Hy-
perChem 7.5.52 Energy restraints were applied to the bond angles
of complexes to maintain square-planar geometries under a
molecular mechanics (MM+) forceﬁeld, and were minimised to a
root-mean-square gradient of 0.2 kJ A˚−1 mol−1. Cisplatin charge
distribution was based on the ab initio analysis of Pavankumar
et al.53 Charges of multinuclear complexes were distributed evenly
among the ligands, and the chloride ligand charge distribution
was based on the molecular mechanics analysis of other Pt(II)
compounds by Battle et al.54 The complexes were modelled in
different starting orientations. The energies were calculated for
comparison using MM+ with the energy restraints removed.
452 | Dalton Trans., 2006, 451–458 This journal is © The Royal Society of Chemistry 2006
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Results
Encapsulation of cisplatin
Although the primary focus of our research is the encapsulation
of multinuclear platinum anticancer drugs, it was of interest to
examine the interaction of cisplatin with cucurbituril. Cisplatin is
a charge neutral complex unlike the multinuclear platinum drugs.
Hence, it was anticipated that cisplatin encapsulation would be
different but relevant to the understanding of the encapsulation
of multinuclear platinum drugs. Consequently, the interaction
between Q[7] and cisplatin was studied by 1H and 195Pt NMR.
Fig. 2 shows the 1H NMR spectrum of Q[7] and Q[7] with added
cisplatin in a metal complex to cucurbituril ratio (R) of 1. Upon
addition of cisplatin, the Q[7]-CH resonance at 5.58 ppm splits
into two peaks (5.63 and 5.55 ppm). One resonance is shifted
marginally upﬁeld and exhibits signiﬁcant line broadening, while
the other resonance is relatively sharp and is shifted marginally
downﬁeld. A similar pattern for the resonances from the non-
equivalent Q[7]-CH2 protons is also observed. The broadened and
shifted resonances are consistent with one (or more) bound form
being in fast to intermediate exchange with free Q[7], with another
cisplatin bound form being in slow exchange (sharp resonances)
with the free cucurbituril and the other bound form(s).
Fig. 2 1H NMR spectra showing (A) Q[7] and (B) Q[7] with added
cisplatin at R = 1 in D2O at 25 ◦C.
It is normal for an equilibrium to be established between the
chloro- and aqua-forms of cisplatin when the platinum complex
is dissolved in slightly acidic water (Fig. 3A), with Pt resonances
for cis-[PtCl2(NH3)2] and cis-[PtCl(NH3)2(H2O)]+ being observed
at −2160 and −1854 ppm respectively, consistent with literature
values.55 Both of these forms of cisplatin can associate with Q[7].
Upon addition ofQ[7] a second resonance is observed in the region
of the chloro form at −2109 ppm, while the resonance due to the
Fig. 3 195Pt NMR spectra showing (A) cisplatin and (B) cisplatin with
added Q[7] at R = 1 in D2O at 25 ◦C.
aqua form has signiﬁcantly shifted to −1890 ppm (see Fig. 3B). A
single resonance for the aqua formmay suggest quantitative bind-
ing toQ[7]with slowexchangekinetics, ormore likely, bindingwith
fast to intermediate exchange (on the 195Pt NMR time scale).More
signiﬁcantly, the observation of separate resonances for free and
bound chloro forms indicates slow exchange kinetics, suggesting
that a fraction of the chloro formof cisplatin binds insideQ[7]. En-
capsulation of cisplatin byQ[7] is consistentwith the reported crys-
tal structure of the metal complex cis-[SnCl4(OH2)2] encapsulated
by Q[7].45 Whereas, the cis-[PtCl(NH3)2(H2O)]+ complex would be
expected to bind only to the portal of Q[7], where it can maximise
the electrostatic interactions and possibly form hydrogen bonds.
Encapsulation of di-Pt
Fig. 4 shows the 1H NMR spectrum of free di-Pt (A) and di-Pt
with added Q[7] (B). The assignments of the resonances from
the metal complex were made from NOESY experiments and
depth proﬁling.56 Molecular models of the Q[7]-encapsulated di-
Pt complex indicated that the dpzm H3 protons were closer to
the dpzm methylene protons than the H5. It was predicted from
the distances to the methylene protons that the NOE to H3
would be 1.4 times more intense than that to H5. Hence, H3 was
assigned to the downﬁeld resonance (∼7.3 ppm)with the strongest
NOE from the dpzm methylene protons (∼3.0 ppm). The upﬁeld
resonance at ∼6.3 ppm was assigned to H5. The encapsulation
model (see below) indicated that any NOE cross-peaks observed
between dpzm and Q[7] protons would be signiﬁcantly weaker
than those observed between protons within the dpzm ligand,
because the Q[7] protons project away from the cucurbituril cavity.
While several very weak intermolecular NOE cross-peaks were
observed in long mixing time NOESY spectra between dpzm and
Q[7] protons, they could not be used to provide any quantitative
distance information. However, the lack of strong intermolecular
Fig. 4 1H NMR spectra showing (A) di-Pt and (B) di-Pt with added Q[7]
at R = 1 and (C) di-Pt with added Q[8] at R = 1 in D2O at 25 ◦C.
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Table 1 1H NMR chemical shifts of the platinum complexes di-Pt and tri-Pt encapsulated by Q[7] and Q[8], and the change in chemical shift from the
free metal complex in brackets (negative numbers indicate upﬁeld shifts)
Chemical shift (ppm)
Complex H5 H5* H3 H3* –CH2–
di-Pt–Q[7] 6.29 (−1.49) a 7.37 (−0.37) a 2.94 (−0.88)
di-Pt–[Q8] 6.84 (−0.94) a 7.28 (−0.46) a 3.06 (−0.76)
tri-Pt–Q[7] 6.32 (−1.54) 6.48 (−1.36) 7.30 (−0.53) 7.71 (−0.08) 3.02 (−0.84)
tri-Pt–Q[8] 6.84 (−1.02) 7.05 (−0.79) 7.23 (−0.60) 7.44 (−0.35) 3.12 (−0.74)
a = Not applicable.
NOE interactions is consistent with the proposed encapsulation
model. From experiments with Q[6] and various aminoalkanes
it was found that the protons further inside Q[6] exhibited the
greatest upﬁeld shift in the 1H NMR spectra due to shielding
effects.56 Furthermore, protons that on average are located outside
but near the portal exhibit slight downﬁeld shifts.56,57 Molecular
models indicated that the H5 proton is further inside Q[7] thanH3
(see below), and hence showed the largest upﬁeld shift of 1.49 ppm
(see Table 1).
As separate resonances for the free and Q[7]-encapsulated di-Pt
were observed at R > 1 (results not shown), it is concluded that
the metal complex binds with slow exchange kinetics on the NMR
time scale.
The resonances from the Q[8]-bound di-Pt (Fig. 4C) were
assigned using molecular modelling and depth proﬁling. Models
of di-Pt encapsulated in Q[8] indicated that that the distances
from the H3 and H5 protons to the dpzm methylene protons
were very similar, and hence assignments could not be obtained
from a NOESY spectrum. However, changes in the chemical
shifts of the resonances from di-Pt suggested Q[8]-encapsulation
was again centred on the dpzm linker rather than the platinum
centres. Consequently, the H3, which is closer to the platinum
centre, will be located less deeply in the Q[8] cavity, regardless
of the pyrazolyl–methylene torsion angles. Therefore, the upﬁeld
resonance (6.64 ppm) is again assigned to the H5, with downﬁeld
resonance at 7.28 ppm being assigned to the H3.
Encapsulation of di-Pt byQ[8] induced large upﬁeld shifts of the
dpzm resonances (see Fig. 4C), with the di-Pt H3 and methylene
resonances shifting by a similar amount to that observed for Q[7]-
encapsulation; however, the H5 resonance shifted upﬁeld by only
0.94 ppm compared to 1.49 ppm for Q[7]-encapsulation. This
indicates that the platinum complex is positioned, on average,
differently in Q[8] than in Q[7]. In addition, the resonance due
to the remaining unexchanged (with the D2O) ammine protons
of di-Pt shifted downﬁeld upon Q[7]-encapsulation and upﬁeld
upon Q[8]-encapsulation. This suggests that the ammine protons
are located on average deeper into the portal opening of Q[8],
but outside and near the portal of Q[7]. Although it can not
be clearly seen in Fig. 4, the dpzm resonances of the Q[8]-
encapsulated di-Pt are signiﬁcantly broader than was observed
for Q[7]-encapsulation, e.g. the width at half-height of the H3
resonance is 2.5 Hz and 9.7 Hz for Q[7]- and Q[8]-encapsulation
respectively. This suggests that the exchange rate between the Q[8]-
encapsulated di-Pt and the free metal complex is faster than for
Q[7]-encapsulation, consistent with the increased portal size.
The 1H NMR spectrum for the hydrolysed-form of di-Pt and
the hydrolysed-form of di-Pt with added Q[7] as a function of time
after mixing is shown in Fig. 5. Prior to encapsulation with Q[7],
complete hydrolysis of di-Pt was conﬁrmed by 195Pt NMR. The Pt
resonance of di-Pt at −2327 ppm was absent and a resonance
for the aqua complex observed at −2042 ppm. As expected,
large upﬁeld shifts of the resonances in the 1H NMR spectra are
observed for the dpzm resonances, indicating the hydrolysed di-Pt
is also encapsulated byQ[7]; however, almost 24 hours are required
for all the platinum complex to be encapsulated.Whereas, di-Pt (Cl
form) is rapidly encapsulated by Q[7] (less than the time required
for mixing and accumulation of the 1H NMR spectrum). This
indicates that it is considerably more difﬁcult for the +2 platinum
centre obtained upon hydrolysis of di-Pt to pass through the Q[7]
portal.
Fig. 5 1H NMR spectra showing (A) the hydrolysed form of di-Pt and
with added Q[7] (B) 30 min, (C) 8 hours and (D) 15 hours after mixing.
Encapsulation of tri-Pt
Fig. 6 shows the 1H NMR spectrum of free tri-Pt and tri-Pt with
added Q[7] and Q[8] at R = 0.5 (i.e. 2 cucurbiturils per platinum
complex). At R = 0.5 each linking dpzm ligand was encapsulated.
Encapsulation by either Q[7] or Q[8] induces signiﬁcant upﬁeld
shifts for the tri-Pt resonances (see Table 1), with the H5/H5*
resonances exhibiting greater shifts than the H3/H3* resonances,
as was observed for di-Pt encapsulation. The magnitude of the
shifts for the H5/H5* and H3/H3* resonances upon Q[7] and
Q[8] encapsulation is different, indicating that tri-Pt adopts a
different binding orientation with Q[7] compared to Q[8]. Upon
encapsulation of tri-Pt, the Q[7] resonance at 5.8 ppm splits into
twodoublets, indicating that the initially symmetric pair of protons
(one from each CH2) of the cucurbituril are non-equivalent. This
loss of symmetry is presumably due to the different nature of
the terminal and central platinum centres, as has been observed
454 | Dalton Trans., 2006, 451–458 This journal is © The Royal Society of Chemistry 2006
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Fig. 6 1HNMR spectra showing (A) tri-Pt and (B) tri-Pt with added Q[7]
at R = 0.5 and (C) tri-Pt with added Q[8] at R = 0.5 in D2O at 25 ◦C.
with other cucurbituril bound guests,57 and may indicate that
the cucurbituril is positioned closer to one platinum centre than
the other. As the central platinum centre carries a +2 charge, it
would be expected that the cucurbituril would preferentially be
positioned closer to it than the mono-cationic terminal platinums.
In further support of this suggestion the magnitudes of the upﬁeld
shifts of H5* and H3* are signiﬁcantly larger than that of H5 and
H3. This indicates that H5* and H3* are closer to the centre of
the cavity than H5.
Fig. 7 shows the 1H NMR spectrum of the hydrolysed tri-Pt
(conﬁrmed by 195Pt NMR) and the metal complex with added Q[7]
at R> 1 (i.e. excess metal complex). In addition to the resonances
observed for the free tri-Pt–aqua, small peaks are seen for the
Q[7]-encapsulated tri-Pt–aqua. One set of tri-Pt–aqua H5/H5*
and H3/H3* resonances (6.30, 6.32, 7.38, 7.40 ppm) are shifted
Fig. 7 1H NMR spectra showing (A) the hydrolysed form of tri-Pt and
with added Q[7] at (B) R = 7.5 and (C) R = 2.5.
upﬁeld, while the other H5/H5* and H3/H3* set of resonances
(7.74, 7.77, 7.86 and 7.90 ppm) do not shift or shift marginally
downﬁeld. The set of aromatic resonances that shift upﬁeld is
consistent with the respective atoms being positioned inside Q[7],
and the protons from the set of resonances showing little or no
downﬁeld shifts being located outside Q[7]. This suggests that the
limiting Q[7] only encapsulates one of the two dpzm ligands of tri-
Pt–aqua, and, as the resonances are in the slow exchange regime,
the results indicate that Q[7] can not pass easily over the central
dicationic platinum centre.
Molecular modelling
Modelling indicated that the encapsulation of di-Pt and tri-Pt by
eachof the cucurbiturilswas favourable compared to association at
the portal or no binding at all. Encapsulation of the multinuclear
platinum complexes distorted the cucurbituril from its normal
spherical shape.46 The optimal geometries for encapsulation of di-
Pt by Q[7] and Q[8] were almost symmetrical (Fig. 8), relative to
the distance between the two portals, with the dpzm methylene
group positioned near the centre of the cucurbituril, in terms
of depth but close to the cavity wall. The dpzm-H5 protons
of di-Pt are located near the three-dimensional centre of Q[7],
with the corresponding H3 protons positioned more towards the
portals, consistent with the larger upﬁeld shift observed in NMR
experiments of theH5 resonance upon encapsulation.As the dpzm
methylene protons exhibit a smaller upﬁeld shift than the H5
resonance, it is concluded that the maximum shielding region
is located at the three-dimensional centre of the cucurbituril.
Smaller upﬁeld shifts are observed as the proton is positioned
either towards the walls of the cavity or the portals. For Q[8]-
encapsulation, the H5 proton was positioned more centrally than
H3 for only one of the two pyrazolyl groups, consistent with the
smaller upﬁeld shift observed for the H5 with Q[8]-encapsulation.
This is due to the torsion angles around the bond between the
Fig. 8 Molecular model of di-Pt encapsulated in (A) Q[7] and (B) Q[8]
generated using HyperChem. The platinum complex was inserted into the
cucurbituril in a variety of different starting positions. Energy minimisa-
tion of the encapsulated-di-Pt was then carried out to convergence.
This journal is © The Royal Society of Chemistry 2006 Dalton Trans., 2006, 451–458 | 455
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pyrazolyl rings and the methylene being larger, bringing the Pt
centres 1.4 A˚ closer together and angling the terminal ligands
back towards the Q[8] cavity and the H5 protons towards the
portal (Fig. 8). The minimisation algorithm produced a similar
conformation when the electrostatic component of the MM+
force ﬁeld was inactivated, suggesting electrostatic interaction
with the portals at most reinforced a conformation determined
predominantly by hydrophobic interactions within the conﬁnes of
the larger Q[8] cavity.
The binding model of tri-Pt by two Q[7] molecules (see Fig. 9)
also suggested encapsulation centred on the dpzm bridging
ligands, with the dpzmmethylene andH5 protons located towards
the centre, in terms of depth, but with the methylene protons
again close to the cavity wall. The H3 protons are located inside
Q[7], but more towards the portals than the corresponding H5,
and the terminal ligands outside the portals. This conformation
was consistent with the much larger upﬁeld shift of the H5
resonances, compared to the H3 resonances observed in the 1H
NMR experiments.
Fig. 9 Molecular model of tri-Pt encapsulated in (A) Q[7] and (B) Q[8]
generated using HyperChem. The platinum complex was inserted into the
cucurbituril in a variety of different starting positions. Energy minimisa-
tion of the encapsulated-tri-Pt was then carried out to convergence.
Optimised models suggested that Q[8] also preferentially en-
capsulated tri-Pt over the dpzm ligands (see Fig. 9); however,
the smaller upﬁeld shift of the H5/H5* resonances and the
slightly larger upﬁeld shift of the H3/H3* resonances upon Q[8]-
encapsulation suggested a different binding conformation forQ[8].
Optimising the Q[8]-encapsulated tri-Pt geometries from different
starting positions revealed energy minima that were shallower and
higher relative to the globalminimum than those for encapsulation
by Q[7]. These minima included encapsulation of the central
or terminal platinum centres, which could be accommodated,
along with the ammine ligands, inside Q[8], although these
conformations produced a local minima rather than the global
minimum. Alternatively, when the Q[8] was centrally positioned
over each dpzm, aminimised conformation could be achieved that
accounted for the increased shielding of H3 and reduced shielding
for the H5, compared to the Q[7]-encapsulation model, observed
in the 1H NMR spectra. The two Q[8]s are in a similar orientation
but not aligned, possibly to reduce electrostatic repulsion between
the portals. As a result the central platinum was at an angle to the
portal of each Q[8] that allowed it to project an ammine ligand
into each portal, which may have also reduced effective inter-Q[8]
portal–portal repulsion, because the ammine ligands carried some
of the positive charge. This angle also oriented both pyrazolyls
joined to the central platinum such that each N1 imido proton
(H1) projected out of each Q[8] cavity towards the portal of the
other Q[8], enabling an additional electrostatic attraction, as the
H1 also carried some of the positive charge. H1 and H5 are bound
to adjacent atomsof the pyrazolyl ring, so such anattractionwould
oppose deeper H5 encapsulation and account for the lower upﬁeld
shift observed when encapsulated by Q[7]. The two terminal
platinum centres of tri-Pt minimised to conformations with the
pyrazolyl rings rotated further around the methylene bonds for
a more compact form with the Pt centres and terminal ligands
rotated towards the cavity and the H5 rotated slightly towards the
portal. This dpzm-encapsulated conformation allowed the Q[8]s
to come close enough to each other to encapsulate all four dpzm
H3 protons of tri-Pt, and therefore better reﬂected the observed
changes in the proton chemical shifts.
Discussion
This paper reports our investigation into the encapsulation of
multinuclear platinum complexes by cucurbit[n]uril (Q[n]). This
study was undertaken with the view that cucurbituril has the
capacity to act as an effective drug delivery vehicle for the
following reasons. The internal cavity is hydrophobic and capable
of encapsulating the aliphatic or aromatic linking ligands of multi-
nuclear platinum drugs. Secondly, the oxygen-rimmed portals
could stabilise the encapsulation of the metal complexes through
electrostatic interactions and hydrogen bonds with the platinum–
ammine groups, and could sterically hinder attack by biological
nucleophiles. It is hoped that encapsulation of metal complexes
within cucurbituril will allow it to be transported through the
body, minimising deactivation or degradation by nucleophilic
plasma proteins. Preliminary studies have indicated that the in vivo
tolerance, based on a 10% weight loss, of Q[7] when administered
intravenously inmice is 200mgkg−1. This ismany times in excess of
the amount required for a delivery system of platinum complexes
that are active at the mg kg−1 level.10,17
The well established anticancer drug cisplatin was initially
investigated for encapsulation within Q[7]. Cisplatin as a neutral
complex has two possible binding modes available with any cucur-
bituril, either cavity or portal binding. Portal binding can occur
through stabilisation by electrostatic interactions and hydrogen-
bonding between the cucurbituril oxygens and the cisplatin
ammine protons. The 1HNMR results indicated that at least some
of the cisplatin bound with medium to fast exchange kinetics,
while the 195Pt NMR indicated slow exchange kinetics (195Pt NMR
time scale). These results suggested that some cisplatin was fully
encapsulated within the cucurbituril cavity, with the remaining
cisplatin presumably binding weakly at the portal. The cavity
bound cisplatin is consistent with results obtainedwith other small
neutral metal complexes, e.g. cis-[SnCl4(H2O)2] which has been
shown by X-ray crystallography to be completely encapsulated
within Q[7].45 In addition, the NMR data suggest that cis-
[PtCl(NH3)2(H2O)]+ only binds Q[7] at the portals, consistent with
the hydrophobic nature of the cucurbituril cavity.
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Unlike cisplatin, the multinuclear platinum complexes bound
quantitatively. Previously we reported, di-Pt binds Q[7] with
slow exchange kinetics with the dpzm ligand being positioned
within the cucurbituril cavity.39 Here we have extended the study
to include the binding of di-Pt to the larger Q[8] and tri-Pt
binding with both Q[7] and Q[8]. The resonances from di-Pt were
signiﬁcantly broader for encapsulation by Q[8], compared to Q[7].
This indicates that the rate of exchange between the encapsulated
and free form is fasterwith the larger cucurbituril, and is consistent
with the larger portal of Q[8] compared to Q[7]. Importantly,
this result indicates that the rate of release of a multinuclear
platinum complex can bemodulated by the size of the cucurbituril.
This could allow the balance between toxicity and cytotoxicity to
be controlled, as slower release could reduce both toxicity and
cytotoxicity. As expected, tri-Pt was encapsulated by Q[7] or Q[8]
in a 1 : 2 ratio, with the kinetics again being slower for Q[7] than
Q[8].
Another important difference between Q[8] and Q[7] encap-
sulation is the effect of the larger cavity size on the orientation
of the pyrazolyl rings of the platinum complex and their relative
relationship. Molecular modelling suggests that the torsion angles
between the pyrazolyl rings in the dpzm ligand of di-Pt are
signiﬁcantly altered for Q[8] binding. The freedom of rotation
about the C–C bonds of the CH2 bridging group is increased
in the larger cavity and as a consequence the platinum centres are
retracted into the portals. The distances between themetal centres,
for minimised geometry, are ∼10.1 and ∼8.7 A˚ for Q[7] and Q[8]
respectively. This is consistent with the 1H NMR results, where
the ammine resonance shifted upﬁeld uponQ[8] encapsulation but
downﬁeldwithQ[7]. The retraction of the platinumcentres into the
portals could result in their greater protection from nucleophilic
plasma and thiol containing proteins. Furthermore, given that the
minimum possible distance between the Pt–Pt centres in vacuo is
6.6 A˚, further protection could be possible with even larger Q
cavities e.g. Q[9] or Q[10].40 Similar reductions in the distances
between Pt–Pt centres were also found for the tri-Pt complexes.
Q[7] was shown to encapsulate the hydrolysed formof di-Pt, and
based upon the similarity of the chemical shifts of the boundmetal
complex, it can be concluded that the cucurbituril was positioned
in a similar fashion to the Cl form of di-Pt. However, of greater
interest was the slower rate of encapsulation of the aqua form of
di-Pt compared to the Cl form. This could be expected, given the
energy cost of the +2 charge of a platinum centre passing through
an electronegative cucurbituril portal to effect encapsulation of the
linking dpzm ligands. Although the hydrolysed form of platinum
anticancer drugs are more toxic than the corresponding Cl form,
the very slow association/dissociation rates could result in a large
decrease in toxicity, as the platinum complex would be released
more slowly. While we have no data to support this possibility,
the results with the aqua form of the di-Pt again highlight the
potential of cucurbiturils as a platinum drug delivery system.
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